Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation

CompletedOBSERVATIONAL
Enrollment

86

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Secondary Hyperparathyroidism
Trial Locations (13)

125284

Site Reference ID/Investigator# 58356, Moscow

127015

Site Reference ID/Investigator# 58348, Moscow

191104

Site Reference ID/Investigator# 57363, Saint Petersburg

420045

Site Reference ID/Investigator# 57346, Kazan'

423450

Site Reference ID/Investigator# 57348, Al'met'yevsk

428018

Site Reference ID/Investigator# 57347, Cheboksary

443095

Site Reference ID/Investigator# 69687, Samara

454076

Site Reference ID/Investigator# 58347, Chelyabinsk

460040

Site Reference ID/Investigator# 57364, Orenburg

630120

Site Reference ID/Investigator# 57342, Novosibirsk

670031

Site Reference ID/Investigator# 69688, Ulan-Ude

677019

Site Reference ID/Investigator# 67404, Iakutsk

664079 RF

Site Reference ID/Investigator# 57344, Irkutsk

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Almedis

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY